Welcome to our dedicated page for Helius Med Technologies SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage device makers like Helius Medical Technologies often bury pivotal updates—FDA feedback on PoNS, reimbursement milestones, cash-runway details—inside dense exhibits. Missing a single line about a new multiple-sclerosis study could upend your valuation. Stock Titan’s AI surfaces those details instantly, turning every line of the Helius Medical Technologies annual report 10-K simplified into clear, actionable data.
Need Helius Medical Technologies SEC filings explained simply? You’ll receive real-time alerts the moment a Helius Medical Technologies quarterly earnings report 10-Q filing or Helius Medical Technologies 8-K material events explained hits EDGAR. Understanding Helius Medical Technologies SEC documents with AI feels intuitive, not technical—section-by-section summaries spotlight device revenue, clinical-trial costs, and capital raises.
- Insider moves: Track Helius Medical Technologies Form 4 insider transactions real-time and pinpoint buying or selling before the market reacts.
- Executive pay: Drill into each Helius Medical Technologies proxy statement executive compensation without scrolling past pages of tables.
- Event catalysts: Rapidly assess 8-K disclosures on clinical results, supply agreements, or VA purchasing contracts.
From Helius Medical Technologies earnings report filing analysis to monitoring Helius Medical Technologies insider trading Form 4 transactions, coverage spans every form. Need a quick read on Helius Medical Technologies executive stock transactions Form 4? It’s already on your dashboard, complete with AI-powered commentary. Compare quarter-over-quarter PoNS unit sales, watch cash levels, and gauge regulatory momentum in minutes—all with Stock Titan’s real-time, AI-driven insight engine.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 180,028 shares of Helius Medical Technologies Class A common stock, representing 4.99% of the class. The filing shows shared voting and shared dispositive power over those shares and states Armistice is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., which holds the securities. The Master Fund disclaims beneficial ownership due to its investment management agreement. The reporting persons certify the securities are held in the ordinary course of business and not to change or influence control of the issuer.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 640 shares of Helius Medical Technologies common stock, comprised of 203 direct common shares and 437 shares underlying warrants. The holding represents 1.01% of the company's outstanding common stock on a post-reverse-split basis, and the filer states sole voting and dispositive power over all 640 shares. The filing references an earlier Schedule that covered 214,050 shares and warrants purchased in the same offering and explains the company completed a 1-for-50 reverse stock split that affected the share counts. Two directors of the reporting fund are named and may be deemed to beneficially own the securities but disclaim such ownership for other purposes.
Helius Medical Technologies (HSDT) received a Schedule 13G/A filed by CVI Investments, Inc. and Heights Capital Management, Inc. The filers state they collectively hold 0 shares, representing 0% of the Class A common stock, and that ownership is at or below the 5% threshold. Heights Capital is identified as the investment manager to CVI and may be deemed to have voting and dispositive power over CVI's shares, while each party disclaims beneficial ownership except for any pecuniary interest.
The filing references a previously filed limited power of attorney and a joint filing agreement and contains no disclosure of an acquisition, disposition, or group control.
Helius Medical Technologies, Inc. (NASDAQ: HSDT) filed an 8-K (Item 8.01) announcing an updated Prospectus Supplement that refreshes its June 2023 at-the-market (ATM) Sales Agreement with Roth Capital Partners. The supplement permits the Company to sell up to US$25 million of registered Class A common stock on Nasdaq or other permitted venues.
• Shares will be issued under the existing S-3 Registration Statement (File No. 333-270433) and qualify as Rule 415(a)(4) “at-the-market offerings.”
• Sales may occur at prevailing or negotiated market prices.
• Use of proceeds: working capital and general corporate purposes, including commercialization and R&D.
• Honigman LLP provided the accompanying legal opinion (Exhibit 5.1) with related consent (Exhibit 23.1).
- The filing does not state how many shares have been sold to date or provide financial metrics.
- No changes to the underlying Sales Agreement terms were disclosed; the update primarily refreshes the prospectus amount.
This 8-K does not constitute an offer to sell securities; it merely notifies investors of the updated prospectus that enables future capital raises via the established ATM facility.
FAQ
What is the current stock price of Helius Med Technologies (HSDT)?
What is the market cap of Helius Med Technologies (HSDT)?
